Sentynl Therapeutics
As of the edition of 20 October 2026, Sentynl Therapeutics runs 4 drugs, 4 of them marketed; it is on route A at 0 targets and on route B at 2 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Fentanyl | none listed | 6 |
| Lonafarnib | Ends 2027 (exclusivity) | 3 |
| Copper histidine | Ends 2033 (exclusivity) | 0 |
| Fosdenopterin | Ends 2028 (exclusivity) | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 2 targets.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Sentynl Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Inherited and neonatal: 2 trials led
- Nervous system: 2 trials led
- Nutrition and metabolism: 2 trials led